ArticleMolecular cancer therapeutics2022

Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β.

Emad Darvishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.